Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes

Trial Profile

Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Insulin aspart (Primary) ; Insulin detemir
  • Indications Type 1 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms Onset 1
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 13 Jun 2017 Results of a post hoc analysis presented at the 77th Annual Scientific Sessions of the American Diabetes Association
    • 13 Jun 2017 Results of post hoc analysis evaluating mealtime (MT) fast-acting insulin aspart (faster aspart), 20 min post-meal (PT) faster aspart and MT insulin aspart (IAsp), each with insulin detemir, presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
    • 13 Jun 2017 Results of post hoc analysis evaluating methods for adjusting the dose of mealtime fast-acting insulin aspart (faster aspart) and insulin aspart (IAsp), each with insulin detemir, presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top